Regulation of Medicines in Bhutan: Current Status, Challenges and Opportunities
Journal Title: International Journal of Drug Regulatory Affairs - Year 2018, Vol 6, Issue 2
Abstract
Medicines Regulatory Agencies (MRAs) are responsible for evaluation of quality, safety and efficacy of medicinal products before it is approved for consumption. The regulatory procedures, however, differs from one country to another. Medical products including vaccines, blood and blood products, diagnostics and medical devices are essential for healthcare delivery across the world. The Drug Regulatory Authority (DRA) is an independent national agency for regulation of medicinal products in Bhutan and reports to Bhutan Medicines Board (BMB), the highest policy making body for regulation of medicinal products in the country. Medicines Act of the Kingdom of Bhutan is the legal tool for regulation of medicines in Bhutan. Medicinal products are regulated through premarketing and post-marketing control systems. All medicinal products available in the Bhutanese market are registered. DRA regulates all the medicinal products including vaccines, blood products and traditional medicines used for human and veterinary. DRA is fully financed by the Government of Bhutan. Bhutan’s medicines regulatory system has evolved over the last one decade. However, as the regulatory mandate continues to increase, DRA is faced with several challenges in terms of human resource, infrastructure and testing laboratory among others. There are also opportunities for the DRA to improve its regulatory capacities to ensure availability of quality and safe medicines for the public. Understanding the current practice of medicines regulation in Bhutan can help identify gaps and existing opportunities for improving the regulatory capacity. This article documents the existing practices, challenges and opportunities for regulation of medicinal products in Bhutan.
Authors and Affiliations
Pelden Chejor, Jigme Tenzin
Keywords
Related Articles
- EP ID EP329326
- DOI 10.22270/ijdra.v6i2.243
- Views 109
- Downloads 0
CONCEPT OF 505 (b) (2) APPLICATION: BENEFITS AND CHALLENGES
A 505(b) (2) application is a new drug application (NDA) delineated in section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.505(b)(2) application is one that one or a lot of the investigations relied upon by the...
A critical view of harmonization of regulatory requirements for Generic Drug approval submissions in ASEAN countries
To ensure quality, efficacy, and safety of drugs is the prime objective of any country and respective drug regulatory authority. Countries have their own regulatory setup to ensure the proper execution of drug regulatory...
Regulatory aspects for Biologic product licensing in India
Biologics are the medicinal/ therapeutic/ diagnostic/ preventive preparations composed or derived from living organisms and their spin-off for human use. They include serums, vaccines, antitoxins, blood, antigens and blo...
Comparative study of the harmonization of pharmaceutical regulations in the western and central sub-regions of Africa
The harmonization of pharmaceutical regulations in Africa aims to offer States a coherent body of texts and practices by combining limited resources. The objective of this study was to describe policies to harmonize phar...
Transnail drug delivery device:A prominent approach for Onychomycosis therapy
Onychomycosis is often challenging therapeutically and demands a multipronged approach both in terms of systemic as well as topical delivery. The conventional treatment modalities available for onychomycosis are marred w...